Idexx Laboratories Inc vs. Intellia Therapeutics, Inc
Idexx Laboratories Inc (IDXX) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| IDXX | NTLA | |
|---|---|---|
| Market Cap | $39.90 billion | $1.72 billion |
| Revenue (TTM) | $4.55 billion | $59.51 million |
| Net Income (TTM) | $1.14 billion | $-399,975,000 |
IDXX leads on 3 of 3 size & scale factors.
Valuation
| IDXX | NTLA | |
|---|---|---|
| P/E Ratio | 35.96 | — |
| Price / Book | 24.74 | 2.36 |
| Price / Sales | 8.76 | 28.87 |
IDXX and NTLA split the valuation factors evenly.
Profitability
| IDXX | NTLA | |
|---|---|---|
| Net Margin | 25.03% | -672.16% |
| Return on Equity | 70.67% | -54.96% |
IDXX leads on 2 of 2 profitability factors.
Risk & Sentiment
| IDXX | NTLA | |
|---|---|---|
| Short Interest | 1.79% | 2.43% |
IDXX leads on 1 of 1 risk & sentiment factors.
Dig deeper: IDXX overview, IDXX financials, NTLA overview, NTLA financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.